245 related articles for article (PubMed ID: 19384296)
1. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.
Gusella M; Frigo AC; Bolzonella C; Marinelli R; Barile C; Bononi A; Crepaldi G; Menon D; Stievano L; Toso S; Pasini F; Ferrazzi E; Padrini R
Br J Cancer; 2009 May; 100(10):1549-57. PubMed ID: 19384296
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
[TBL] [Abstract][Full Text] [Related]
3. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
[TBL] [Abstract][Full Text] [Related]
4. Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab.
Budai B; Komlósi V; Adleff V; Pap É; Réti A; Nagy T; Kralovánszky J; Láng I; Hitre E
Pharmacogenet Genomics; 2012 Jan; 22(1):69-72. PubMed ID: 22044939
[TBL] [Abstract][Full Text] [Related]
5. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
6. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
[TBL] [Abstract][Full Text] [Related]
7. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
8. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Martinez-Balibrea E; Abad A; Martínez-Cardús A; Ginés A; Valladares M; Navarro M; Aranda E; Marcuello E; Benavides M; Massutí B; Carrato A; Layos L; Manzano JL; Moreno V
Br J Cancer; 2010 Aug; 103(4):581-9. PubMed ID: 20628391
[TBL] [Abstract][Full Text] [Related]
9. MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.
Negandhi AA; Hyde A; Dicks E; Pollett W; Younghusband BH; Parfrey P; Green RC; Savas S
PLoS One; 2013; 8(4):e61469. PubMed ID: 23626689
[TBL] [Abstract][Full Text] [Related]
10. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J
Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798
[TBL] [Abstract][Full Text] [Related]
11. Association of C677T and A1298C
Ramos-Esquivel A; Chinchilla R; Valle M
Anticancer Res; 2020 Aug; 40(8):4263-4270. PubMed ID: 32727753
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
Onesti CE; Botticelli A; La Torre M; Borro M; Gentile G; Romiti A; Lionetto L; Petremolo A; Occhipinti M; Roberto M; Falcone R; Simmaco M; Marchetti P; Mazzuca F
Anticancer Drugs; 2017 Mar; 28(3):322-326. PubMed ID: 27845948
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Yeh CC; Lai CY; Chang SN; Hsieh LL; Tang R; Sung FC; Lin YK
Int J Clin Oncol; 2017 Jun; 22(3):484-493. PubMed ID: 28044213
[TBL] [Abstract][Full Text] [Related]
14. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
Afzal S; Gusella M; Vainer B; Vogel UB; Andersen JT; Broedbaek K; Petersen M; Jimenez-Solem E; Bertolaso L; Barile C; Padrini R; Pasini F; Jensen SA; Poulsen HE
Clin Cancer Res; 2011 Jun; 17(11):3822-9. PubMed ID: 21471424
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
[TBL] [Abstract][Full Text] [Related]
16. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.
Etienne MC; Formento JL; Chazal M; Francoual M; Magné N; Formento P; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
Pharmacogenetics; 2004 Dec; 14(12):785-92. PubMed ID: 15608557
[TBL] [Abstract][Full Text] [Related]
17. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
Paré L; Altés A; Ramón y Cajal T; Del Rio E; Alonso C; Sedano L; Barnadas A; Baiget M
Anticancer Drugs; 2007 Aug; 18(7):821-5. PubMed ID: 17581305
[TBL] [Abstract][Full Text] [Related]
18. Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Soveri LM; Hermunen K; de Gramont A; Poussa T; Quinaux E; Bono P; André T; Österlund P
Eur J Cancer; 2014 Nov; 50(17):2966-74. PubMed ID: 25266443
[TBL] [Abstract][Full Text] [Related]
19. Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.
Fernández-Peralta AM; Daimiel L; Nejda N; Iglesias D; Medina Arana V; González-Aguilera JJ
Int J Colorectal Dis; 2010 Feb; 25(2):141-51. PubMed ID: 19669769
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
